Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03997123 · ClinicalTrials.gov registry record · Phase 3
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
A Phase 3 study of Triple Negative Breast Neoplasms, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 923
- Enrollment target
- 20
- Study locations
NCT03997123: Active Phase 3 study of Triple Negative Breast Neoplasms, sponsored by AstraZeneca.
NCT03997123 is a Phase 3 study of Triple Negative Breast Neoplasms that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 923 participants, above the 571-participant average among 10 other Triple Negative Breast Neoplasms trials with a reported enrollment target (62% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03997123, a Phase 3 study of Triple Negative Breast Neoplasms, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 923 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)
Primary Outcome
Overall Survival (OS)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Paclitaxel
- DRUG Capivasertib
Study Locations (20)
Florida
- Research Site - Fort Myers
- Research Site - Miami
- Research Site - St. Petersburg
- Research Site - Tampa
Pennsylvania
- Research Site - Harrisburg
- Research Site - Philadelphia
- Research Site - Pittsburgh
Texas
- Research Site - Austin
- Research Site - Fort Worth
- Research Site - Houston
California
- Research Site - Whittier
- Research Site - Whittier
Ohio
- Research Site - Cincinnati
- Research Site - Columbus
Illinois
- Research Site - Chicago
Kansas
- Research Site - Westwood
Maryland
- Research Site - Silver Spring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 923 participants |
| Start Date | 2019-06-25 |
| Est. Completion | 2026-03-16 |
| Phase | Phase 3 |
What the registry record for NCT03997123 still lists
NCT03997123 is an interventional study that assigns participants to a tested intervention. The registered 923 participants enrollment target is mid-sized for trials with a published cap, above the 571-participant average among 10 other Triple Negative Breast Neoplasms trials with a reported enrollment target (62% higher).
The record links to 1 condition, with Triple Negative Breast Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03997123 names 20 study sites across 11 states, led by Florida, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT03997123 about?
NCT03997123 is a clinical study titled "Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC". Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)
What is the current status of trial NCT03997123?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 923 participants. The study started on 2019-06-25. Estimated completion is 2026-03-16.
What conditions does trial NCT03997123 study?
This clinical trial studies the following conditions: Triple Negative Breast Neoplasms.
What interventions are being tested in trial NCT03997123?
The interventions under investigation include: Placebo (DRUG), Paclitaxel (DRUG), Capivasertib (DRUG).
Who is sponsoring clinical trial NCT03997123?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03997123 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03997123's enrollment target sits among peer trials
923 3rd of 10 higher than 8 of 10 other Triple Negative Breast Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Triple Negative Breast Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RECRUITING · Phase 3
-
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RECRUITING · Phase 3
-
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
ACTIVE NOT RECRUITING · Phase 3
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04692493 · 924 participants · Phase 3
Ra-pro Pragmatic Trial
- NCT05656807 · 924 participants · NA
Evaluation of Child Care Staff Weight Management Program
- NCT06082453 · 924 participants · NA
Modernizing Perinatal Syphilis Testing
- NCT07151001 · 922 participants
Pivotal Trial of Automated Artificial Intelligence (AI) Based System for Early Diagnosis of Diabetic Retinopathy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI